These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 15505753)

  • 1. Neuroimaging trials of Parkinson's disease progression.
    Seibyl J; Jennings D; Tabamo R; Marek K
    J Neurol; 2004 Oct; 251 Suppl 7():vII9-13. PubMed ID: 15505753
    [No Abstract]   [Full Text] [Related]  

  • 2. The harsh realities facing the use of SPECT imaging in monitoring disease progression in Parkinson's disease.
    Morrish PK
    J Neurol Neurosurg Psychiatry; 2003 Oct; 74(10):1447; author reply 1447. PubMed ID: 14570850
    [No Abstract]   [Full Text] [Related]  

  • 3. How valid is dopamine transporter imaging as a surrogate marker in research trials in Parkinson's disease?
    Morrish PK
    Mov Disord; 2003 Oct; 18 Suppl 7():S63-70. PubMed ID: 14531048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional imaging in Parkinson's disease and dementia with Lewy bodies.
    Colloby S; O'Brien J
    J Geriatr Psychiatry Neurol; 2004 Sep; 17(3):158-63. PubMed ID: 15312279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroimaging in Parkinson's disease.
    Brooks DJ
    NeuroRx; 2004 Apr; 1(2):243-54. PubMed ID: 15717025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroimaging and transcranial ultrasonography in Parkinson's disease.
    Mehta SH; Morgan JC; Sethi KD
    Curr Neurol Neurosci Rep; 2008 Jul; 8(4):297-303. PubMed ID: 18590613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging end points for monitoring neuroprotection in Parkinson's disease.
    Brooks DJ
    Ann Neurol; 2003; 53 Suppl 3():S110-8; discussion S118-9. PubMed ID: 12666103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The meaning of negative DAT SPECT and F-Dopa PET scans in patients with clinical Parkinson's disease.
    Morrish P
    Mov Disord; 2005 Jan; 20(1):117; author reply 117-8. PubMed ID: 15468100
    [No Abstract]   [Full Text] [Related]  

  • 9. [Diagnostic use of functional imaging in Parkinson's disease and related disorders].
    Hanakawa T; Kawasaki K; Hashikawa K; Fukuyama H
    Nihon Rinsho; 2004 Sep; 62(9):1733-8. PubMed ID: 15462394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Neuroimaging in Parkinson's disease].
    Hilker R; Steinmetz H
    Nervenarzt; 2010 Oct; 81(10):1159. PubMed ID: 20857277
    [No Abstract]   [Full Text] [Related]  

  • 11. Neuroimaging advances in Parkinson's disease.
    Rispoli V; Schreglmann SR; Bhatia KP
    Curr Opin Neurol; 2018 Aug; 31(4):415-424. PubMed ID: 29878908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug development parameters for functional imaging in neurosciences.
    Otte A; Wink K
    Hell J Nucl Med; 2007; 10(2):80-1. PubMed ID: 17684581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of neuroimaging in the early diagnosis and evaluation of Parkinson's disease.
    Seibyl J; Jennings D; Tabamo R; Marek K
    Minerva Med; 2005 Oct; 96(5):353-64. PubMed ID: 16227950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine agonists and Parkinson's disease progression: what can we learn from neuroimaging studies.
    Marek K; Jennings D; Seibyl J
    Ann Neurol; 2003; 53 Suppl 3():S160-6; discussion S166-9. PubMed ID: 12666107
    [No Abstract]   [Full Text] [Related]  

  • 15. How useful is (123I) beta-CIT SPECT in the diagnosis of Parkinson's disease?
    Bhidayasiri R
    Rev Neurol Dis; 2006; 3(1):19-22. PubMed ID: 16596082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. α-synuclein imaging: a critical need for Parkinson's disease research.
    Eberling JL; Dave KD; Frasier MA
    J Parkinsons Dis; 2013; 3(4):565-7. PubMed ID: 24192754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional imaging of cognitive impairment in Parkinson's disease.
    Fitzpatrick T; Mattis P; Eidelberg D
    Clin EEG Neurosci; 2010 Jul; 41(3):119-26. PubMed ID: 20722344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of radiotracer imaging in Parkinson disease.
    Zweig RM; Lilien DL; Tainter K; Patterson J
    Neurology; 2005 Oct; 65(7):1144-5; author reply 1144-5. PubMed ID: 16220586
    [No Abstract]   [Full Text] [Related]  

  • 19. Camptocormia: as the first sign of Parkinson's disease.
    Oh YS; Kim JS; Chung SW; Kim YD; Lee KS
    Can J Neurol Sci; 2011 Mar; 38(2):370-2. PubMed ID: 21473177
    [No Abstract]   [Full Text] [Related]  

  • 20. DaTscan and Parkinson's disease: DAT binding should not lead to binding decisions in clinical practice.
    de la Fuente-Fernández R; Lövblad KO
    Eur J Neurol; 2014 Nov; 21(11):1351-2. PubMed ID: 24837615
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.